EBITDA 40 35
36.1
33.8
30.7
29.8
28.4
Millions of euros
30 25
20 15 10 5
0 I Q 09
2Q09
3Q09
4Q09
1Q10
Consolidated EBIT rose from 24,405,000 euros in the first three months of 2009 to 31,522,000 euros in 2010, for a year-over-year increase of 29.2%.
EBIT 35 Millions of euros
30
31.5
29.5 25.4
24.4
26.1
25 20 15 10 5
0 I Q 09
2Q09
3Q09
4Q09
1Q10
Lastly, the Group earned a net profit of 19,518,000 euros in the first quarter of 2010, for a gain of 48.3% compared with the 13,161,000 euros earned in the same period last year. A significant development that occurred during the first three months of 2010 was the announcement by Diasorin S.p.A., on March 10, 2010, that it had signed a binding agreement to buy the MUREX速 product line from the Abbott Group. The MUREX速 product line, which is based on the ELISA technology, consists mainly of products to diagnose HIV, HCV and HBV. Subject to the fulfillment of the customary conditions precedent, this transaction is expected to close in the second quarter of 2010. In addition, the branch in the People's Republic of China, which became a commercial company at the beginning of 2010, began handling direct sales. A consolidated income statement for the quarters ended March 31, 2010 and 2009 is provided below. 7